Aldosterone in the development and progression of renal injury

Slides:

Advertisements

Similar presentations

Human tissue kallikrein gene delivery attenuates hypertension, renal injury, and cardiac remodeling in chronic renal failure William C. Wolf, Hideaki.

Advertisements

Volume 54, Pages S135-S139 (December 1998)

A.M. Thompson, T.G. Pickering Kidney International

Antioxidant Treatment Prevents Renal Damage and Dysfunction and Reduces Arterial Pressure in Salt-Sensitive Hypertension by Niu Tian, Kristina D. Thrasher,

Differential Effects of Angiotensin II Type-1 Receptor Antisense Oligonucleotides on Renal Function in Spontaneously Hypertensive Rats by Minoru Yoneda,

M.S. Mozaffari, C. Patel, R. Abdelsayed, S.W. Schaffer

Plasma sodium and hypertension

Volume 61, Issue 4, Pages (April 2002)

Prenatal exposure to nicotine modifies kidney weight and blood pressure in genetically susceptible rats: A case of gene-environment interaction Zdenka.

Volume 64, Issue 2, Pages (August 2003)

Progression of renal failure and hypertensive nephrosclerosis

Volume 54, Issue 6, Pages (January 1998)

Volume 61, Issue 5, Pages (May 2002)

Volume 59, Issue 5, Pages (May 2001)

Overcoming barriers that inhibit proper treatment of anemia

Malignant Hypertension

Endothelial-derived vasoactive mediators in polycystic kidney disease

Volume 68, Issue 4, Pages (October 2005)

Volume 63, Issue 5, Pages (May 2003)

Prenatal programming of adult hypertension in the rat

F. Yi, A.Y. Zhang, N. Li, R.W. Muh, M. Fillet, A.-F. Renert, P.-L. Li

Volume 76, Issue 3, Pages (August 2009)

Xiuqing Wang, Zhongjie Sun, Robert Cade Kidney International

Volume 59, Issue 3, Pages (March 2001)

Volume 56, Issue 5, Pages (November 1999)

Volume 81, Issue 3, Pages (February 2012)

Volume 70, Issue 11, Pages (December 2006)

Volume 91, Issue 5, Pages (May 2017)

Human tissue kallikrein gene delivery attenuates hypertension, renal injury, and cardiac remodeling in chronic renal failure William C. Wolf, Hideaki.

Up-regulation of kidney NAD(P)H oxidase and calcineurin in SHR: Reversal by lifelong antioxidant supplementation Chang-de Zhan, Ram K. Sindhu, Nosratola.

Volume 68, Issue 6, Pages (December 2005)

Volume 69, Issue 10, Pages (May 2006)

Volume 64, Issue 1, Pages (July 2003)

Volume 62, Issue 3, Pages (September 2002)

Volume 63, Issue 1, Pages (January 2003)

B. Li, T. Morioka, M. Uchiyama, T. Oite Kidney International

SYMPLICITY: not all that simple

Peroxisome proliferator-activated receptor-gamma agonist is protective in podocyte injury-associated sclerosis H.-C. Yang, L.-J. Ma, J. Ma, A.B. Fogo

Volume 82, Issue 7, Pages (October 2012)

Proteinuria and hypertensive nephrosclerosis in African Americans

Role of endothelin and nitric oxide imbalance in the pathogenesis of hypoxia-induced arterial hypertension Zhenmin Ni, Shahrooz Bemanian, Salah D. Kivlighn,

Urinary biomarkers: the future looks promising

Volume 55, Issue 3, Pages (March 1999)

Counteracting progression of renal disease: A look into the future

Neurogenic factors and hypertension in renal disease

Volume 54, Pages S135-S139 (December 1998)

Circadian regulation of renal function

Yasunori Kitamoto, Katsuhiko Matsuo, Kimio Tomita Kidney International

Volume 58, Issue 3, Pages (September 2000)

Volume 55, Issue 3, Pages (March 1999)

Volume 64, Issue 2, Pages (August 2003)

Volume 71, Issue 9, Pages (May 2007)

Volume 63, Issue 1, Pages (January 2003)

The course of the remnant kidney model in mice

Volume 68, Issue 5, Pages (November 2005)

Effect of proteinuria and glomerular filtration rate on cardiovascular risk in essential hypertension Julian Segura, Carlos Campo, Luis M. Ruilope Kidney.

Salt sensitivity in genetically hypertensive rats of the Lyon strain

Is it the low-protein diet or simply the salt restriction?

Volume 75, Issue 1, Pages (January 2009)

Volume 68, Issue 1, Pages (July 2005)

Volume 62, Issue 5, (November 2002)

Volume 58, Issue 2, Pages (August 2000)

Volume 53, Issue 4, Pages (April 1998)

Effect of prenatal dexamethasone on rat renal development

Volume 61, Issue 1, Pages (January 2002)

J. Ma, A. Weisberg, J.P. Griffin, D.E. Vaughan, A.B. Fogo, N.J. Brown

Volume 53, Issue 5, Pages (May 1998)

Volume 73, Issue 11, Pages (June 2008)

Volume 65, Issue 2, Pages (February 2004)

Volume 56, Issue 6, Pages (December 1999)

Presentation transcript:

Aldosterone in the development and progression of renal injury Norman K. Hollenberg Kidney International Volume 66, Issue 1, Pages 1-9 (July 2004) DOI: 10.1111/j.1523-1755.2004.00701.x Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 1 Effect of spironolactone on urinary protein excretion in stroke-prone spontaneously hypertensive rats. Line graphs showing (A) systolic arterial blood pressure (SBP) and (B) urinary protein excretion (UPE) in stroke-prone spontaneously hypertensive rats into which time-release pellets containing spironolactone or placebo were implanted. Values are mean ± SEM. Numbers in parenthesis indicate the number of animals. *P < 0.001 compared with placebo-implanted controls. Reprinted with permission from Rocha et al38. Kidney International 2004 66, 1-9DOI: (10.1111/j.1523-1755.2004.00701.x) Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 2 Vascular pathology of malignant nephrosclerosis in saline-fed stroke-prone spontaneously hypertensive rats. Representative photomicrograph of renal cortex from saline-drinking stroke-prone spontaneously hypertensive after 2 weeks of treatment with vehicle or aldosterone. Typical lesions of malignant nephrosclerosis consist of ischemic or thrombotic glomeruli (large arrows), extensive mural fibrinoid deposits in microvessels (large arrowheads), and fragmented extravasated erythrocytes (small arrowheads). Reprinted with permission from Rocha et al38. Kidney International 2004 66, 1-9DOI: (10.1111/j.1523-1755.2004.00701.x) Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 3 Percent change in urinary albumin:creatinine ratio at week 24 in eplerenone, enalapril, and eplerenone/enalapril patients.*P < 0.001 week 24 vs. baseline for all treatments [abstract; Epstein M, et al, J Am Coll Cardiol 39:Suppl A, 2002]. Kidney International 2004 66, 1-9DOI: (10.1111/j.1523-1755.2004.00701.x) Copyright © 2004 International Society of Nephrology Terms and Conditions